Corteva, Inc. (CTVA)
UndervaluedFundamental
50
मूल्य
$12.12
मार्केट कैप
$53.01B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Corteva sells seeds and crop-protection chemicals to farmers in about 110 countries. It was separated from DowDuPont in 2019, combining the old Pioneer seed genetics business with DuPont's agricultural chemicals. Its products help growers raise yield and fight weeds, insects and fungi on corn, soybeans and other row crops, sold mainly through independent dealers and a direct agency network built around the Pioneer brand.
यह पैसा कैसे कमाती है
Revenue comes from two distinct product sales: branded seed with proprietary genetics and traits (Seed), and herbicides, insecticides and fungicides (Crop Protection). Both are booked when the dealer or farmer takes delivery, concentrated in the planting seasons of each hemisphere. Seed carries higher margins thanks to patented traits; Crop Protection is more exposed to generic competition once patents expire.
सेगमेंट के अनुसार राजस्व
Corn, soybean and other seed sold under the Pioneer and Brevant brands, built on decades of proprietary germplasm and licensed and owned biotech traits.
Herbicides, insecticides, fungicides and biologicals, including newer active ingredients such as Zorvec and Arylex alongside older, more commoditized products.
प्रतिस्पर्धी बढ़त (Moat)
पेटेंट और लाइसेंस · संकीर्णCorteva's germplasm library reflects roughly 90 years of Pioneer breeding and field-testing data, and it holds thousands of patents including its own biotech traits rather than relying only on licenses. That data and IP base is hard to replicate quickly, but Bayer and Syngenta hold comparable positions, so the advantage is real but not exclusive.
मांग को क्या चलाता है
चक्रीयPurchases follow the planting calendar and farmers' expected income: commodity crop prices, input costs and weather in a given season decide how much a grower spends on seed and chemicals that year. A drought, a flood or a slump in corn and soybean prices can compress an entire season's demand quickly.
प्रमुख जोखिम
- Dependence on regulatory approvals — New seed traits and crop-protection products need approval from agencies such as the EPA, USDA and FDA and their equivalents abroad, and countries' rules on genetically modified crops differ and can change, delaying or blocking launches.
- Weather and climate variability — Abnormal weather in a major growing region — drought, excess rain, early frost — reduces both the acreage planted and the demand for crop inputs in that season, and the company cannot offset a bad season with sales elsewhere in the same window.
- Legacy environmental and litigation liabilities — Corteva carries obligations and litigation exposure inherited from its DuPont and Chemours history, including PFAS-related claims and crop-protection product liability suits, which can result in material costs unrelated to current operating performance.
- Competition from generics and major peers — Once a crop-protection active ingredient's patent expires, generic manufacturers can undercut it on price, and Corteva competes across both segments against a small number of very large rivals with comparable scale and research budgets.
- Execution risk of the planned Seed and Crop Protection separation — In October 2025 Corteva announced a plan to split into two independent listed companies. Carrying out that separation involves cost, management distraction and uncertainty over how each resulting company's shared costs and liabilities will be divided.
खरीदने के पक्ष में तर्क
Buyers argue that Corteva's decades of proprietary germplasm and its own biotech traits let it capture more of the value chain than seed rivals who license traits from others, and that splitting Seed from Crop Protection could let each business be valued and managed on its own merits.
बेचने के पक्ष में तर्क
Sellers fear that both segments remain exposed to weather and commodity cycles outside the company's control, that generic competition keeps eroding Crop Protection margins, and that the planned separation adds execution risk and uncertain cost allocation on top of an already cyclical business.
Written by the editors, published on 18 अगस्त 2026
Direct competitors
Who this company fights with for the same customers
Generated on 18 सितंबर 2026 with claude-haiku-4-5 — shared with all users
Bayer's Crop Science division is the only rival that matches Corteva across both of its businesses at once, selling corn and soybean seed with its own herbicide-tolerance traits alongside a full herbicide, fungicide and insecticide range to the same North and South American row-crop farmers.
Syngenta, owned by China's Sinochem and not publicly listed, competes head-on for the same farmer's wallet with a combined seed and crop-protection offer in the Americas, Europe and Asia, and is named as a competitor in Corteva's own 10-K.
BASF's Agricultural Solutions unit sells competing herbicides, fungicides and seed treatments plus its own soybean and canola seed-and-trait systems, going after the same crop-input budget on the same acres.
FMC is a pure crop-protection company whose insecticides and herbicides compete directly with Corteva's Crop Protection segment for the same treatments on corn, soybeans and specialty crops, especially in Brazil and the United States.
UPL is the largest supplier of off-patent crop-protection chemistry and undercuts Corteva's branded herbicides and fungicides once molecules lose exclusivity, particularly in Brazil, India and Eastern Europe.
KWS is a seed-only breeder that competes with Corteva's Pioneer brand for corn, sugar beet and cereal seed sales to European and North American farmers.
बैलेंस शीट और तरलता
राजस्व
$17.81B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$1.01B
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$2.81B
कुल इक्विटी
$24.14B
कुल देनदारियाँ
$18.46B
Current Ratio
1.52
Interest Coverage
-
Debt/EBITDA
0.39
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$65.04
वर्तमान मूल्य
$12.12
Margin of Safety
+81.4%
Fair Value सीमा
$42.27 - $87.80
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
50.75
ROE
4.5%
P/B Ratio
2.06
P/FCF
82.37
Gross Margin
49.5%
ROIC
-
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
-
WACC
7.8%
ROIC − WACC
-
Fundamental विश्लेषण मानदंड
पास (14)
- EPS shows upward trend
- Price CAGR 15.37%
- Gross Margin 49.5%
- P/B Ratio 2.06
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 69% Buy
- Earnings Surprise avg 20.6%
- Earnings Quality (OCF/NI) 1.20
- Share Dilution -2.0%
- Piotroski F-Score 6/9
फेल (9)
- P/FCF 82.37
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 4.1%
- Revenue Growth 5Y 4.1%
- PEG Ratio 4.33
- Net Margin Trend 5.7% vs 8.2%
अनुपलब्ध (4)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Charles Victor Magro B.Sc. (Chem), MBA | CEO & Director | 55 |
| Mr. David P. Johnson | Executive VP & CFO | 57 |
| Dr. Samuel R. Eathington Ph.D. | Executive VP and Chief Technology & Digital Officer | 56 |
| Mr. Cornel B. Fuerer | Senior VP & Strategic Advisor | 58 |
| Mr. Judd M. O'Connor | Executive Vice President of Seed Business Unit | 54 |
| Mr. Brian Titus | VP, Controller & Principal Accounting Officer | 52 |
| Kimberly Booth | Vice President of Investor Relations | - |
| Dr. Jennifer Amy Johnson Ph.D. | Senior VP, Chief Legal & Public Affairs Officer and Corporate Secretary | 50 |
| Ms. Audrey Grimm | Senior VP & Chief People Officer | 44 |
| Mr. Jeffrey Rudolph | Senior VP & Chief Strategy Officer | 42 |
Audit जोखिम
5
बोर्ड जोखिम
3
मुआवजा जोखिम
5
शेयरधारक अधिकार जोखिम
5
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-12
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-07-31
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-10-01
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for CTVA, sourced from Markets Gazette.
- 6h agoNEUTRALCosa sta succedendo al prezzo delle azioni Corteva oggi?
Corteva Inc. (CTVA) shares experienced a significant price adjustment on October 1st, dropping sharply post-market open. This decline is attributed to a planned corporate restructuring, specifically the spin-off of its advanced seed and genetics division into a new, independent publicly traded company named Vylor. While the spin-off itself is a strategic move to create a more focused agricultural group, the immediate market reaction reflects the reallocation of market capitalization. Investors are now evaluating the standalone entities and their future prospects, making the short-term price movement a result of structural change rather than operational performance.
- 8/20/2026NEUTRALVylor Offers High-Grade Debt in Market’s Latest Pre-Spinoff Deal
Corteva Inc. is set to receive a payout from its subsidiary Vylor Inc., which is issuing investment-grade bonds to finance this distribution. This move precedes an anticipated spinoff of Vylor. While the bond offering itself is a financing activity, its direct impact on Corteva's stock is neutral at this stage, as it relates to a subsidiary's financial restructuring and an upcoming separation. Investors will await further details on the terms of the spinoff and the ultimate benefit to Corteva shareholders.
via Markets Gazette